A new research project focusing on rare genetic mutations that are linked to cystic fibrosis just received $600,000 in ...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Alyftrek (triple combination medicine ...
UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...
In two randomised phase 3 studies involving 480 participants aged 12 years and over, ivacaftor/tezacaftor/vanzacaftor was ...
The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...
Cystic fibrosis is an inherited lifelong disease that gets worse over time. It is estimated to affect 105,000 people worldwide. There are more than 2,000 known mutations in the CFTR gene ...
Cystic fibrosis is an inherited lifelong disease that gets worse over time. It is estimated to affect 105,000 people worldwide. There are more than 2,000 known mutations in the CFTR gene ...
Cystic fibrosis is a genetic disorder that adversely ... accounting for approximately 70% of all CFTR mutations. It is estimated that more than 160,000 people worldwide are living with CF ...
Cystic fibrosis is an inherited lifelong disease that gets worse over time. It is estimated to affect 105,000 people worldwide. There are more than 2,000 known mutations in the CFTR gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results